vs

Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and Dexcom (DXCM). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $1.0B, roughly 1.2× Alignment Healthcare, Inc.). Dexcom runs the higher net margin — 21.2% vs -1.1%, a 22.3% gap on every dollar of revenue. On growth, Alignment Healthcare, Inc. posted the faster year-over-year revenue change (44.4% vs 21.6%). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (26.9% CAGR vs 12.0%).

Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

ALHC vs DXCM — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.2× larger
DXCM
$1.3B
$1.0B
ALHC
Growing faster (revenue YoY)
ALHC
ALHC
+22.8% gap
ALHC
44.4%
21.6%
DXCM
Higher net margin
DXCM
DXCM
22.3% more per $
DXCM
21.2%
-1.1%
ALHC
Faster 2-yr revenue CAGR
ALHC
ALHC
Annualised
ALHC
26.9%
12.0%
DXCM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ALHC
ALHC
DXCM
DXCM
Revenue
$1.0B
$1.3B
Net Profit
$-11.0M
$267.3M
Gross Margin
62.9%
Operating Margin
-1.0%
25.6%
Net Margin
-1.1%
21.2%
Revenue YoY
44.4%
21.6%
Net Profit YoY
64.6%
153.6%
EPS (diluted)
$-0.04
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALHC
ALHC
DXCM
DXCM
Q1 26
$1.3B
Q4 25
$1.0B
$1.3B
Q3 25
$993.7M
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$926.9M
$1.0B
Q4 24
$701.2M
$1.1B
Q3 24
$692.4M
$994.2M
Q2 24
$681.3M
$1.0B
Net Profit
ALHC
ALHC
DXCM
DXCM
Q1 26
$267.3M
Q4 25
$-11.0M
$267.3M
Q3 25
$3.7M
$283.8M
Q2 25
$15.7M
$179.8M
Q1 25
$-9.1M
$105.4M
Q4 24
$-31.1M
$151.7M
Q3 24
$-26.4M
$134.6M
Q2 24
$-24.0M
$143.5M
Gross Margin
ALHC
ALHC
DXCM
DXCM
Q1 26
62.9%
Q4 25
62.9%
Q3 25
60.5%
Q2 25
59.5%
Q1 25
56.9%
Q4 24
58.9%
Q3 24
59.7%
Q2 24
62.4%
Operating Margin
ALHC
ALHC
DXCM
DXCM
Q1 26
25.6%
Q4 25
-1.0%
25.6%
Q3 25
0.8%
20.1%
Q2 25
2.2%
18.4%
Q1 25
-0.6%
12.9%
Q4 24
-3.2%
17.0%
Q3 24
-2.8%
15.3%
Q2 24
-2.7%
15.7%
Net Margin
ALHC
ALHC
DXCM
DXCM
Q1 26
21.2%
Q4 25
-1.1%
21.2%
Q3 25
0.4%
23.5%
Q2 25
1.5%
15.5%
Q1 25
-1.0%
10.2%
Q4 24
-4.4%
13.6%
Q3 24
-3.8%
13.5%
Q2 24
-3.5%
14.3%
EPS (diluted)
ALHC
ALHC
DXCM
DXCM
Q1 26
$0.67
Q4 25
$-0.04
$0.67
Q3 25
$0.02
$0.70
Q2 25
$0.07
$0.45
Q1 25
$-0.05
$0.27
Q4 24
$-0.15
$0.37
Q3 24
$-0.14
$0.34
Q2 24
$-0.13
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALHC
ALHC
DXCM
DXCM
Cash + ST InvestmentsLiquidity on hand
$604.2M
$917.7M
Total DebtLower is stronger
$323.2M
Stockholders' EquityBook value
$179.3M
$2.7B
Total Assets
$1.1B
$6.3B
Debt / EquityLower = less leverage
1.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALHC
ALHC
DXCM
DXCM
Q1 26
$917.7M
Q4 25
$604.2M
$917.7M
Q3 25
$644.1M
$1.8B
Q2 25
$503.8M
$1.2B
Q1 25
$479.5M
$904.9M
Q4 24
$470.6M
$606.1M
Q3 24
$381.0M
$621.2M
Q2 24
$363.7M
$939.2M
Total Debt
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
$323.2M
Q3 25
$322.7M
Q2 25
$322.3M
Q1 25
$321.9M
Q4 24
$321.4M
Q3 24
$212.0M
Q2 24
$211.7M
Stockholders' Equity
ALHC
ALHC
DXCM
DXCM
Q1 26
$2.7B
Q4 25
$179.3M
$2.7B
Q3 25
$161.9M
$2.7B
Q2 25
$141.0M
$2.6B
Q1 25
$108.1M
$2.3B
Q4 24
$99.9M
$2.1B
Q3 24
$114.5M
$2.0B
Q2 24
$123.7M
$2.4B
Total Assets
ALHC
ALHC
DXCM
DXCM
Q1 26
$6.3B
Q4 25
$1.1B
$6.3B
Q3 25
$1.1B
$7.5B
Q2 25
$1.0B
$7.3B
Q1 25
$895.6M
$6.8B
Q4 24
$782.1M
$6.5B
Q3 24
$692.3M
$6.4B
Q2 24
$716.3M
$6.8B
Debt / Equity
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
1.80×
Q3 25
1.99×
Q2 25
2.29×
Q1 25
2.98×
Q4 24
3.22×
Q3 24
1.85×
Q2 24
1.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALHC
ALHC
DXCM
DXCM
Operating Cash FlowLast quarter
$-50.4M
Free Cash FlowOCF − Capex
$-55.4M
FCF MarginFCF / Revenue
-5.5%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$113.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
$-50.4M
$294.0M
Q3 25
$144.6M
$659.9M
Q2 25
$29.1M
$303.0M
Q1 25
$16.6M
$183.8M
Q4 24
$-8.7M
$301.4M
Q3 24
$26.2M
$199.5M
Q2 24
$23.5M
$279.4M
Free Cash Flow
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
$-55.4M
$192.1M
Q3 25
$139.1M
$579.4M
Q2 25
$21.1M
$208.9M
Q1 25
$8.4M
$96.8M
Q4 24
$-18.0M
$176.8M
Q3 24
$16.9M
$88.3M
Q2 24
$11.8M
$213.3M
FCF Margin
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
-5.5%
15.3%
Q3 25
14.0%
47.9%
Q2 25
2.1%
18.1%
Q1 25
0.9%
9.3%
Q4 24
-2.6%
15.9%
Q3 24
2.4%
8.9%
Q2 24
1.7%
21.2%
Capex Intensity
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
0.5%
8.1%
Q3 25
0.6%
6.7%
Q2 25
0.8%
8.1%
Q1 25
0.9%
8.4%
Q4 24
1.3%
11.2%
Q3 24
1.3%
11.2%
Q2 24
1.7%
6.6%
Cash Conversion
ALHC
ALHC
DXCM
DXCM
Q1 26
Q4 25
1.10×
Q3 25
38.77×
2.33×
Q2 25
1.86×
1.69×
Q1 25
1.74×
Q4 24
1.99×
Q3 24
1.48×
Q2 24
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons